IND filings are possible for rhGGF2 for these
indications...
multiple sclerosis
muscle wasting
muscle injury
peripheral neuropathies
myasthenia gravis
muscular dystrophies
spinal cord injuries
nerve regeneration
diabetic neuropathy
chemo-induced neuropathies
cancer: breast, ovarian, brain
I don't know how that last one showed up on
the list...maybe it is an error.
This is obviously a big grab bag, and
how recap got those entries I have no idea.
Soon shareholders of Cambridge NeuroScience
should have one of those half-yearly letters
in our hands, and then it will be a lot easier
to speculate on which goes off first, probably MS.
If CNSI should need delivery beyond the blood/brain
barrier, maybe they can team up with my #2 pick,
ctii for their encapsulation technology, neuro
CRIB I think it is named...but this is darts again.
(and your points on the CytoTherapeutics thread
were not lost on me...however, Cyto has managed to
accumulate scores of patents, so who knows?)
So, to answer your question...I do not think that
Alzheimer's dementia or Parkinson's disease is on
CNSI's list.
Also, I know I am very early jumping on CNSI, but
I have a thing about getting in super cheap. I will
grow out of this condition in time. I suppose the
time to really load up is after a lot more mice
are sacrificed and CNSI shows up on the FDA server.
Up all night with new eyeglasses, and headed for
the tallest pile on my desk now!
--Mike |
